Biosimilar drugs to provide safe, effective treatment
The Alberta Government is changing coverage for biologics under the Alberta Drug Benefit List (ABDL). Public coverage for patients currently on certain originator biologics will be transitioned to biosimilars. This affects both patients who are new to biologics, and patients already receiving originators. Our Executive Director, Alberta/Nunavut/NWT, Suzan Valenta, is quoted.
Back to News
Share